167 related articles for article (PubMed ID: 27025923)
1. Prevalence and incidence of liver enzyme elevations in a pooled oncology clinical trial cohort.
Shantakumar S; Landis S; Lawton A; Hunt CM
Regul Toxicol Pharmacol; 2016 Jun; 77():257-62. PubMed ID: 27025923
[TBL] [Abstract][Full Text] [Related]
2. A proposed modification to Hy's law and Edish criteria in oncology clinical trials using aggregated historical data.
Parks D; Lin X; Painter JL; Cheng J; Hunt CM; Spraggs CF; Nelson JJ; Curtis L; Menius JA; Lee KR
Pharmacoepidemiol Drug Saf; 2013 Jun; 22(6):571-8. PubMed ID: 23300062
[TBL] [Abstract][Full Text] [Related]
3. Validation of multivariate outlier detection analyses used to identify potential drug-induced liver injury in clinical trial populations.
Lin X; Parks D; Painter J; Hunt CM; Stirnadel-Farrant HA; Cheng J; Menius A; Lee K
Drug Saf; 2012 Oct; 35(10):865-75. PubMed ID: 22928730
[TBL] [Abstract][Full Text] [Related]
4. Background incidence of liver chemistry abnormalities in a clinical trial population without underlying liver disease.
Weil JG; Bains C; Linke A; Clark DW; Stirnadel HA; Hunt CM
Regul Toxicol Pharmacol; 2008 Nov; 52(2):85-8. PubMed ID: 18585425
[TBL] [Abstract][Full Text] [Related]
5. Transaminase Levels and Hepatic Events During Tocilizumab Treatment: Pooled Analysis of Long-Term Clinical Trial Safety Data in Rheumatoid Arthritis.
Genovese MC; Kremer JM; van Vollenhoven RF; Alten R; Scali JJ; Kelman A; Dimonaco S; Brockwell L
Arthritis Rheumatol; 2017 Sep; 69(9):1751-1761. PubMed ID: 28597609
[TBL] [Abstract][Full Text] [Related]
6. Liver Safety of Fasiglifam (TAK-875) in Patients with Type 2 Diabetes: Review of the Global Clinical Trial Experience.
Marcinak JF; Munsaka MS; Watkins PB; Ohira T; Smith N
Drug Saf; 2018 Jun; 41(6):625-640. PubMed ID: 29492878
[TBL] [Abstract][Full Text] [Related]
7. Incidence and prevalence of abnormal liver associated enzymes in patients with atrial fibrillation in a routine clinical care population.
Makar GA; Weiner MG; Kimmel SE; Bennett D; Burke A; Yang YX; Han X; Sellers K; Nessel L; Lewis JD
Pharmacoepidemiol Drug Saf; 2008 Jan; 17(1):43-51. PubMed ID: 17960855
[TBL] [Abstract][Full Text] [Related]
8. In silico modeling to optimize interpretation of liver safety biomarkers in clinical trials.
Church RJ; Watkins PB
Exp Biol Med (Maywood); 2018 Feb; 243(3):300-307. PubMed ID: 29096561
[TBL] [Abstract][Full Text] [Related]
9. Drug-induced liver injury in hospitalized patients with notably elevated alanine aminotransferase.
Xu HM; Chen Y; Xu J; Zhou Q
World J Gastroenterol; 2012 Nov; 18(41):5972-8. PubMed ID: 23139615
[TBL] [Abstract][Full Text] [Related]
10. High-dose frequency beta-interferons increase the risk of liver test abnormalities in multiple sclerosis: a longitudinal study.
Chan S; Kingwell E; Oger J; Yoshida E; Tremlett H
Mult Scler; 2011 Mar; 17(3):361-7. PubMed ID: 21148660
[TBL] [Abstract][Full Text] [Related]
11. Clinical pattern of zileuton-associated liver injury: results of a 12-month study in patients with chronic asthma.
Watkins PB; Dube LM; Walton-Bowen K; Cameron CM; Kasten LE
Drug Saf; 2007; 30(9):805-15. PubMed ID: 17722971
[TBL] [Abstract][Full Text] [Related]
12. Methotrexate treatment in rheumatoid arthritis and elevated liver enzymes: A long-term follow-up of predictors, surveillance, and outcome in clinical practice.
Karlsson Sundbaum J; Eriksson N; Hallberg P; Lehto N; Wadelius M; Baecklund E
Int J Rheum Dis; 2019 Jul; 22(7):1226-1232. PubMed ID: 31012257
[TBL] [Abstract][Full Text] [Related]
13. Clinical observation of liver chemistry abnormalities in asthmatics.
Katz DA; Isaacson JD; Han L; Drajesk JF; Comer GM; Heath-Chiozzi ME
Curr Drug Saf; 2009 Sep; 4(3):173-80. PubMed ID: 19534645
[TBL] [Abstract][Full Text] [Related]
14. A pre-marketing ALT signal predicts post-marketing liver safety.
Moylan CA; Suzuki A; Papay JI; Yuen NA; Ames M; Hunt CM
Regul Toxicol Pharmacol; 2012 Aug; 63(3):433-9. PubMed ID: 22668747
[TBL] [Abstract][Full Text] [Related]
15. What are the best reference values for a normal serum alanine transaminase activity (ALT)? Impact on the presumed prevalence of drug induced liver injury (DILI).
M'Kada H; Munteanu M; Perazzo H; Ngo Y; Ramanujam N; Imbert-Bismut F; Ratziu V; Bonnefont-Rousselot D; Souberbielle B; Schuppe-Koistinen I; Poynard T;
Regul Toxicol Pharmacol; 2011 Aug; 60(3):290-5. PubMed ID: 21539883
[TBL] [Abstract][Full Text] [Related]
16. Alanine aminotransferase: a clinical and regulatory tool for detecting liver injury-past, present, and future.
Senior JR
Clin Pharmacol Ther; 2012 Sep; 92(3):332-9. PubMed ID: 22871997
[TBL] [Abstract][Full Text] [Related]
17. Background incidence of liver chemistry abnormalities in pediatric clinical trials for conditions with and without underlying liver disease.
Stirnadel HA; Bains C; Lakshmi M; Pandey R; Webb DJ; Irizarry MC; Hunt CM
Regul Toxicol Pharmacol; 2012 Mar; 62(2):329-35. PubMed ID: 22057095
[TBL] [Abstract][Full Text] [Related]
18. Use of Hy's law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury.
Robles-Diaz M; Lucena MI; Kaplowitz N; Stephens C; Medina-Cáliz I; González-Jimenez A; Ulzurrun E; Gonzalez AF; Fernandez MC; Romero-Gómez M; Jimenez-Perez M; Bruguera M; Prieto M; Bessone F; Hernandez N; Arrese M; Andrade RJ; ; ;
Gastroenterology; 2014 Jul; 147(1):109-118.e5. PubMed ID: 24704526
[TBL] [Abstract][Full Text] [Related]
19. HLA-B*57:01 Confers Susceptibility to Pazopanib-Associated Liver Injury in Patients with Cancer.
Xu CF; Johnson T; Wang X; Carpenter C; Graves AP; Warren L; Xue Z; King KS; Fraser DJ; Stinnett S; Briley LP; Mitrica I; Spraggs CF; Nelson MR; Tada H; du Bois A; Powles T; Kaplowitz N; Pandite LN
Clin Cancer Res; 2016 Mar; 22(6):1371-7. PubMed ID: 26546620
[TBL] [Abstract][Full Text] [Related]
20. Significance of alanine aminotransferase levels in patients admitted for cocaine intoxication.
Guollo F; Narciso-Schiavon JL; Barotto AM; Zannin M; Schiavon LL
J Clin Gastroenterol; 2015 Mar; 49(3):250-5. PubMed ID: 24518798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
